China’s National Medical Products Administration (NMPA) has granted approval for Helio Genomics’ sister business Laboratory for Advanced Medicine and Health Group’s (LAMH) cfDNA liver cancer detection test.
It is claimed to be the first liquid biopsy test approved by NMPA for liver cancer, marking a milestone in the field of blood-based cancer detection.
Using advanced genomic technology, the test helps in early diagnosis of the most common form of liver cancer, hepatocellular carcinoma.
Helio Genomics chief scientific officer Dr David Taggart said: “Our team has worked tirelessly to develop a solution that combines our scientific expertise, cutting-edge technology and a deep understanding of the genetic diversity in the Asia-Pacific region.
“We believe this approval will have a profound impact on patient outcomes by enabling the detection of liver cancers at an earlier stage when curative treatment is more likely.”
The approved product is the HelioLiver test’s variation, created by the same core scientific team and this advanced test has been specifically developed to suit the people in Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
LAMH intends to transform liver cancer surveillance and improve patient care in China by tailoring the product to the regional population.
For seamless integration and maximum reach of the test, the company plans to partner with key stakeholders, healthcare providers and medical institutions.
Helio Genomics CEO Justin Chen Li said: “This significant milestone represents the culmination of years of dedicated research and development by our exceptional scientific team.
“LAMH’s success in gaining regulatory approval in China reinforces our commitment to improving healthcare outcomes for diverse populations worldwide.”